Silence Therapeutics PLC Silence to present at Cowen Health Care Conference (5989G)

TIDMSLN

RNS Number : 5989G

Silence Therapeutics PLC

05 March 2018

Silence Therapeutics to Present at the Cowen 38th Annual Health Care Conference

London, 5(th) March 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that Ali Mortazavi, Chief Executive Officer, will present at the Cowen 38th Annual Health Care Conference on Tuesday, 13 March, 2018 at 10:30am EDT in Boston, MA.

The presentation will be webcast live and may be accessed by visiting Silence's website at http://www.silence-therapeutics.com/investors/. A replay of the webcast will be available for 14 business days.

Enquiries:

 
 Silence Therapeutics plc            Tel: +44 (0)20 3457 
  Ali Mortazavi, Chief Executive      6900 
  Officer 
  David Ellam, Chief Financial 
  Officer 
 
   Peel Hunt LLP (Nominated            Tel: +44 (0)20 7418 
   Adviser and Broker)                 8900 
   James Steel/Oliver Jackson 
 Media Enquiries: 
  Optimum Strategic Communications     Tel: +44 (0) 20 3714 
  Mary Clark/ Eva Haas/Hollie          1788 
  Vile 
  silence@optimumcomms.com 
 IR Enquires - US                    Tel: +1 (212) 213 
  Burns McClellan                     0006 
  John Grimaldi

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCJTMFTMBIMBIP

(END) Dow Jones Newswires

March 05, 2018 02:00 ET (07:00 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024